• 1
    Beals JM, Shanafelt AB. Enhancing exposure of protein therapeutics. Drug Discov Today Techn 2006; 3: 8794.
  • 2
    De Kort M, Gianotten B, Wisse JAJ, Bos ES, Eppink MHM, Mattaar E, Vogel GMT, Dokter WHA, Honing M, Vonsovic S, Smit M-J, Wijkmans JCHM, van Boeckel CAA. Conjugation of ATIII-binding pentasaccharides to extend the half-life of proteins: long-acting insulin. Chem Med Chem 2008; 3: 11891193.
  • 3
    Pickup JC, Renard E. Long-acting insulin analogs vs. Insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008; 31: (Suppl 2): S140S145.
  • 4
    Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174183.
  • 5
    Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003; 25: 15411577.
  • 6
    Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006; 7: 325343.
  • 7
    Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9: 648659.
  • 8
    Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstack J, Pinget M, Mathieu C. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011; 377: 924931.
  • 9
    Veyrat-Follet C, Vivier N, Trellu M, Dubruc C, Sanderink GJ. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost 2009; 7: 559565.
  • 10
    Watanabe M, Hayasaki H, Tamayama T, Shimada M. Histologic distribution of insulin and glucagon receptors. Braz J Med Biol Res 1998; 31: 243256.
  • 11
    Bos ES, de Kort M, Smit MJ, van Boeckel CAA. PCT. Pat. Appl. WO/2006/082184, 2006, 95.